Thermo Fisher Scientific’s (TMO – Q4FY19 & FY19) – QIAGEN acquisition – a long-term strategy.

in , on March 16, 2020

TMO  significantly strengthened its pharma services network in 2019 by acquiring leading viral vector manufacturer Brammer Bio and the GSK active pharmaceutical ingredient manufacturing site in Ireland and expanding production capacity at facilities in North America and Europe to support
growing demand for biologics and gene therapies.

 Executive Summary

Financial Statements

– Income Statement and Forecast
– Balance Sheet
– Cash Flow
– Q4FY19 Results – Overview
– FY19 Results – Overview
– Q4FY19 – Segment Performance
– FY20 Guidance
– Conclusion
– GAAP to Non-GAAP Reconciliation

 Historical Performance

– Key Ratios
– Profitability Ratios, Asset Turnover Ratio, Growth Ratio
– DuPont Analysis
– Return on Invested Capital
– Per Share Items and Key Ratios
– Key Balance Sheet and Cash Flow Items
– P/E Band

 Product Performance and Key Developments

– Ownership
– Competitors
– Key Developments

Valuation and Consensus Performance

– Relative Valuation
– Analyst Recommendations

Market Price Performance

 CrispIdea Coverage

Release Information

  • Released
    :

    March 16, 2020

  • Last Updated
    :

    March 18, 2020